Publication | Closed Access
Normalization of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure.
51
Citations
0
References
1987
Year
Lipoprotein LipaseRenal PathologyHyperlipidemiaEighteen PatientsMetabolic SyndromeRenal FunctionChronic Renal FailureLipoprotein AbnormalitiesChronic Kidney DiseaseDyslipidemiaLipid DisorderHealth SciencesHigh-density Lipoprotein CholesterolBiochemistryKidney FailureLiver PhysiologyPharmacologyUrologyRenal DiseaseHepatologyCardiovascular DiseaseDiabetesGemfibrozil ResultsLipoprotein MetabolismMedicineNephrology
Eighteen patients with chronic renal failure (serum creatinine 173-756 mumol/l) and hyperlipidemia were treated with gemfibrozil (1200 mg/day). The drug caused a significant improvement of the dyslipidemia within one week and the effect was progressive during the 28 weeks of treatment. Very-low-density lipoprotein triglycerides and very-low-density lipoprotein cholesterol decreased by about 50% and high-density lipoprotein cholesterol increased by 30%. The lipoprotein changes occurred simultaneously with a significant activation to normal levels of postheparin plasma lipoprotein and hepatic lipases. Opposite effects were observed when gemfibrozil was discontinued and the patients were given placebo. No major harmful effects were observed.